ADVM Adverum Biotechnologies, Inc.

2.65
+0  (2%)
Previous Close 2.60
Open 2.65
Price To book 0.50
Market Cap 111.47M
Shares 42,063,000
Volume 149,861
Short Ratio 2.87
Av. Daily Volume 215,134

SEC filingsSee all SEC filings

  1. 8-K - Current report 17775967
  2. 8-K - Current report 17771587
  3. CT ORDER - Confidential treatment order 17751995
  4. 10-Q/A (Amend) - Quarterly report (Sections 13 or 15(d)) 17742574
  5. 8-K - Current report 17712807

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2017.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors
  2. Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy Investor Day
  3. ETFs with exposure to Adverum Biotechnologies, Inc. : April 12, 2017
  4. Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
  5. Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  6. Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  7. Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors
  8. Adverum Biotechnologies posts 4Q loss
  9. Adverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Update
  10. Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?
  11. Adverum Biotechnologies to Present at Upcoming Investor Conferences
  12. Is KCAP Financial Inc (KCAP) A Good Stock to Buy?
  13. Is Osiris Therapeutics, Inc. (OSIR) A Good Stock To Buy?
  14. Is Adverum Biotechnologies Inc (ADVM) a Good Stock to Buy?
  15. ETFs with exposure to Adverum Biotechnologies, Inc. : December 5, 2016
  16. Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016

SEC Filings

  1. 8-K - Current report 17775967
  2. 8-K - Current report 17771587
  3. CT ORDER - Confidential treatment order 17751995
  4. 10-Q/A (Amend) - Quarterly report (Sections 13 or 15(d)) 17742574
  5. 8-K - Current report 17712807
  6. 8-K - Current report 17701508
  7. 8-K - Current report 17688782
  8. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17676448
  9. 8-K - Current report 17666602
  10. 8-K - Current report 17654724